Rensheng Wang
Impact in
- Otorhinolaryngology top 1%
- Head and Neck Cancer Studies
- Cancer Research top 5%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
Papers in
-
- Head and Neck Cancer Studies 48
-
- Cancer-related molecular mechanisms research 22
- MicroRNA in disease regulation 9
Rensheng Wang
126 papers receiving 1.6k citations
Peers
Comparison fields: 5 of 131
- Otorhinolaryngology 405
- Cancer Research 495
- Oncology 334
- Pulmonary and Respiratory Medicine 385
- Molecular Biology 756
Countries citing papers authored by Rensheng Wang
This map shows the geographic impact of Rensheng Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rensheng Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rensheng Wang more than expected).
Fields of papers citing papers by Rensheng Wang
This network shows the impact of papers produced by Rensheng Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rensheng Wang. The network helps show where Rensheng Wang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Rensheng Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 2 | |
| 3 | 2024 | 2 | |
| 4 | 2024 | 12 | |
| 5 | 2024 | 1 | |
| 6 | 2024 | 0 | |
| 7 | 2024 | 4 | |
| 8 | 2024 | 0 | |
| 9 | 2024 | 5 | |
| 10 | 2023 | 7 | |
| 11 | 2022 | 4 | |
| 12 | 2022 | 5 | |
| 13 | 2022 | 12 | |
| 14 | 2022 | 1 | |
| 15 | 2020 | 17 | |
| 16 | 2020 | 21 | |
| 17 | 2018 | 41 | |
| 18 | 2017 | 0 | |
| 19 | Prognostic value of neutrophil to lymphocyte ratio in patients with nasopharyngeal carcinoma: A meta-analysis | 2017 | 4 |
| 20 | Experiment of Radioprotective Early Radiation Damage of Sarcandra Glabra on Salivary Gland:Observe the Tissue Morphology following fractionated Radiation on Head-neck Region in Guinea-pig Models | 2008 | 1 |
About Rensheng Wang
Rensheng Wang is a scholar working on Otorhinolaryngology, Cancer Research, Oncology, Pulmonary and Respiratory Medicine and Radiation, having authored 140 papers that have together received 1.7k indexed citations. Recurring topics across this work include Head and Neck Cancer Studies (48 papers), Cancer-related molecular mechanisms research (22 papers), RNA modifications and cancer (21 papers), Lung Cancer Research Studies (14 papers), Head and Neck Surgical Oncology (11 papers), MicroRNA in disease regulation (9 papers), Lung Cancer Diagnosis and Treatment (9 papers) and Angiogenesis and VEGF in Cancer (9 papers). The work is most often cited by research in Otorhinolaryngology (405 citations), Cancer Research (495 citations), Oncology (334 citations), Pulmonary and Respiratory Medicine (385 citations) and Molecular Biology (756 citations). Rensheng Wang has collaborated with scholars based in China, United States and Sweden. Frequent co-authors include Min Kang, Kai Hu, Yong Zhang, Fang Wu, Meilian Liu, Guisheng Li, Wenqi Liu, Jinxian Zhu, Haolin Yan and Guosheng Feng. Their work appears in journals such as Journal of Clinical Oncology, Frontiers in Oncology, Dose-Response, Medicine and Oncotarget.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.